Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paclitaxel

FDA-approved product (injectable, injection), marketed as Abraxane, Paclitaxel, Taxol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Paclitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • HER2 Positive Breast Carcinoma
  • Kaposi's sarcoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Non-small cell lung carcinoma
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Undifferentiated carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paclitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paclitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis

    NCT00055133 · start 2002-09

    Registered record
    Registry ID
    NCT00055133
    Conditions
    Rheumatoid Arthritis
    Interventions
    Micellar Paclitaxel for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2004-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMicellar Paclitaxel for Injection
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer

    NCT00034164 · start 2002-04

    Registered record
    Registry ID
    NCT00034164
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    S-8184 Paclitaxel Injectable Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-04
    Completion
    2007-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionS-8184 Paclitaxel Injectable Emulsion
    PhasePhase 2
    Registry statusCompleted

  • Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

    NCT00004013 · start 1999-01

    Registered record
    Registry ID
    NCT00004013
    Conditions
    Breast Cancer
    Interventions
    trastuzumab; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-01
    Completion
    2001-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiontrastuzumab; paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

    NCT00003035 · start 1997-03

    Registered record
    Registry ID
    NCT00003035
    Conditions
    Breast Cancer
    Interventions
    filgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate; surgical procedure; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-03
    Completion
    2001-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionfilgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    NCT00021372 · start 1996-02

    Registered record
    Registry ID
    NCT00021372
    Conditions
    Lymphoma
    Interventions
    estramustine phosphate sodium; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-02
    Completion
    2006-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionestramustine phosphate sodium; paclitaxel
    PhasePhase 2
    Registry statusCompleted